Plasmalogen Therapeutics

 

Med-life discoveries is a clinical-stage biopharma company developing novel plasmalogen-based therapeutics for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP) and other neurological conditions*

 

*MLD’s plasmalogen therapeutics are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.

 
neuron_banner_inversed.png
 
 

News

 

Catch up on our latest whereabouts and milestones here!

 
 

Peroxisomal Disorders

Rhizomelic Chondrodysplasia Punctata (RCDP) affects fewer than 100 patients in North America. but there is #hopeforRCDP and other plasmalogen-deficient peroxisomal disorders with PPI-1011: a first-in-class plasmalogen therapy in clinical development

Jackson2_original.jpg

Neurological Conditions

Plasmalogen deficiency is associated with several neurological conditions including alzheimer’s disease, parkinson’s disease, and multiple sclerosis. Therapeutically augmenting plasmalogens represents a new paradigm for the management of these diseases.

 
 
 
 

Literature

relevant literature, curated by our own scientific communications team